Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARAMINE vs ABILIFY MYCITE KIT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Direct-acting sympathomimetic amine that stimulates alpha-adrenergic receptors, causing vasoconstriction and increased blood pressure.
Aripiprazole is a partial agonist at D2 and D3 dopamine receptors and 5-HT1A serotonin receptors, and an antagonist at 5-HT2A serotonin receptors. It also exhibits moderate affinity for histamine H1 receptors and alpha1-adrenergic receptors. The My Cite kit includes a sensor that detects tablet ingestion and transmits data to a wearable patch.
Treatment of hypotension due to certain acute medical conditions (e.g., spinal anesthesia, drug-induced hypotension),Off-label: adjunct in the management of septic shock
Schizophrenia,Acute manic/mixed episodes associated with bipolar I disorder,Maintenance treatment of bipolar I disorder,Major depressive disorder (adjunctive therapy),Irritability associated with autistic disorder,Tourette's disorder
Intravenous infusion: 1-10 mg initially, then 0.5-5 mg/hr titrated to blood pressure. Intramuscular or subcutaneous: 2-10 mg every 2 hours as needed.
Oral: 10-15 mg once daily; dose range 5-30 mg/day; titrate based on response and tolerability. The MYCITE sensor is applied to the tablet; the patch and app are for adherence monitoring only.
Terminal elimination half-life is 2-4 hours. Clinical context: Requires continuous infusion for sustained blood pressure support.
Aripiprazole: 75 hours (range 48–146 h). Dehydro-aripiprazole: 94 hours (range 48–206 h). Steady state reached in 14 days.
Primarily hepatic via oxidative deamination by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT)
Aripiprazole is metabolized primarily by CYP2D6 and CYP3A4. The major active metabolite is dehydro-aripiprazole (formed by CYP2D6). Phase I reactions include dehydrogenation and hydroxylation. Phase II glucuronidation of hydroxylated metabolites occurs.
Primarily renal: 85% unchanged drug in urine within 24 hours. Biliary/fecal: <5%.
Aripiprazole: ~25% renal, ~55% fecal; unchanged drug accounts for <1% renal. Dehydro-aripiprazole (active metabolite): excreted similarly.
Approximately 50-70% bound to albumin and alpha-1 acid glycoprotein.
Aripiprazole: >99% bound to albumin and alpha-1-acid glycoprotein. Dehydro-aripiprazole: >99% bound.
0.5-1.0 L/kg. Clinical meaning: Indicates extensive distribution into tissues, consistent with a polar catecholamine.
Aripiprazole: 4.9 L/kg (IV). High Vd indicates extensive tissue distribution.
Intramuscular: 100%; Subcutaneous: 100%; Oral: negligible (<5%) due to extensive first-pass metabolism.
Oral: 87% (absolute). Tablet and orally disintegrating tablet are bioequivalent.
No specific dose adjustment guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to reduced clearance.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥15 m L/min). Not recommended for severe renal impairment (Cr Cl <15 m L/min) due to lack of data.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to altered metabolism.
Child-Pugh Class A or B: No dose adjustment necessary. Child-Pugh Class C: Use with caution; maximum dose 10 mg/day due to increased exposure.
Intravenous infusion: 0.1-0.2 mg/kg/dose, titrate to effect; maximum 0.5 mg/kg/dose.
Not approved for patients <18 years; safety and effectiveness not established.
Use lower initial doses (e.g., 0.5-1 mg IV) and titrate slowly due to increased sensitivity and risk of hypertension.
No specific dose adjustment; use lower starting doses (e.g., 5 mg/day) due to increased sensitivity and risk of adverse effects, especially orthostatic hypotension and tardive dyskinesia.
None
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Aripiprazole is not approved for the treatment of patients with dementia-related psychosis.
Risk of extravasation leading to tissue necrosis,Use with caution in patients with hypertension, hyperthyroidism, or cardiovascular disease,May cause bradycardia reflexively,Monitor blood pressure closely during administration
Neuroleptic malignant syndrome,Tardive dyskinesia,Metabolic changes including hyperglycemia/diabetes, dyslipidemia, weight gain,Orthostatic hypotension,Falls,Leukopenia/neutropenia/agranulocytosis,Seizures,Body temperature regulation impairment,Dysphagia,Suicidal thoughts/behaviors in adolescents/young adults with MDD
Hypersensitivity to metaraminol or any component,Use with MAO inhibitors (may cause severe hypertensive crisis),Use in patients with pheochromocytoma or severe hypertension
Hypersensitivity to aripiprazole or any component of the formulation,Concurrent use with ziprasidone (QT prolongation risk)
Avoid tyramine-rich foods (e.g., aged cheeses, cured meats, fermented products) if taking MAOIs, but no specific dietary restrictions for metaraminol itself. Maintain adequate hydration as directed.
No specific food interactions are reported for the sensor component. Aripiprazole can be taken with or without food. However, avoid excessive alcohol consumption as it may increase central nervous system depression or worsen side effects. Grapefruit and grapefruit juice do not significantly interact with aripiprazole metabolism (CYP3A4 minor pathway); no restriction needed.
FDA Pregnancy Category C. First trimester: Animal studies show fetal abnormalities; no adequate human studies. Second/third trimester: Risk of maternal hypertension, reduced uterine blood flow; may cause fetal bradycardia, hypoxia, or metabolic acidosis. Avoid in eclampsia.
First trimester: Limited human data; animal studies show developmental toxicity (reduced fetal weight, delayed ossification) at doses similar to human exposure. Second/third trimester: Neonates exposed to antipsychotics (including aripiprazole) during late pregnancy may experience extrapyramidal symptoms and/or withdrawal symptoms (agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder).
No human data. M/P ratio unknown. Excretion likely minimal due to high protein binding; exercise caution. Prefer alternative agents.
Aripiprazole is present in human breast milk; limited data suggest infant serum levels are low but can vary. M/P ratio not established. Caution advised; monitor infant for sedation, irritability, and feeding problems.
Increased plasma volume may require higher initial doses. Titrate to effect; monitor for exaggerated pressor response. No fixed dose adjustment; individualize.
No specific dose adjustment recommended; however, pregnancy may alter aripiprazole pharmacokinetics (decreased exposure due to increased volume of distribution and clearance). Monitor clinical response and consider dose adjustment if efficacy or tolerability changes. Use lowest effective dose.
ARAMINE (metaraminol) is a potent vasopressor used primarily for acute hypotension. Monitor blood pressure frequently, ideally via intra-arterial line, as its duration of action is prolonged (up to 1 hour) and may cause rebound hypertension. Avoid extravasation; central line administration preferred. Tachyphylaxis can occur with prolonged use. It is contraindicated in patients with MAOI use within 14 days due to hypertensive crisis risk.
Abilify My Cite is aripiprazole tablets embedded with an ingestible sensor (Ingestible Event Marker, IEM) that communicates with a wearable patch to record medication ingestion. It is used for schizophrenia, bipolar I disorder, and as adjunctive therapy for major depressive disorder. The sensor does not monitor drug levels or efficacy; it only confirms ingestion. Ensure the patient has a compatible smartphone and the My Cite app. The patch must be replaced weekly. Avoid MRI, CT, or diathermy near the patch; remove if undergoing these procedures. Monitor for aripiprazole side effects: akathisia, metabolic changes, tardive dyskinesia, and neuroleptic malignant syndrome. The ingestible sensor contains copper, magnesium, and silicon; allergy risk is low but possible.
This medication is given intravenously to raise blood pressure during emergencies.,You will be closely monitored with frequent blood pressure checks and possible arterial line.,Report any chest pain, severe headache, or blurred vision immediately.,Inform your healthcare provider of all medications you take, especially antidepressants.,Do not stop or change the dose without medical advice.
Take Abilify My Cite by mouth as directed. The sensor in the tablet activates upon contact with stomach fluid. Wear the My Cite patch on your left upper abdomen, replacing it weekly. Use the My Cite app to scan the tablet's QR code and confirm ingestion. Do not crush or chew the tablet. If a dose is missed, take it as soon as remembered unless it is close to the next dose. Do not double doses.,The patch is not MRI compatible; remove it before any MRI, CT scan, or diathermy procedure. Inform all healthcare providers that you use this system. The patch contains no latex. You may feel a mild sensation when the patch communicates with your phone. Keep your phone nearby (within Bluetooth range) for recording.,Common side effects of aripiprazole include nausea, vomiting, constipation, headache, dizziness, insomnia, restlessness, and weight gain. Seek medical attention for severe muscle stiffness, fever, confusion, irregular heartbeat, or suicidal thoughts. Avoid alcohol and activities requiring mental alertness until you know how this medication affects you.,The ingestible sensor is generally safe, but if you have a sensitivity to copper, magnesium, or silicon, discuss with your doctor. The patch may cause skin irritation; if it persists, stop use and contact your provider.,Do not rely solely on the app to confirm ingestion; it is not a substitute for clinical judgment. Store tablets at room temperature, away from moisture and heat. Keep out of reach of children.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARAMINE vs ABILIFY MYCITE KIT, answered by our medical review team.
ARAMINE is a Vasopressor that works by Direct-acting sympathomimetic amine that stimulates alpha-adrenergic receptors, causing vasoconstriction and increased blood pressure.. ABILIFY MYCITE KIT is a Atypical antipsychotic that works by Aripiprazole is a partial agonist at D2 and D3 dopamine receptors and 5-HT1A serotonin receptors, and an antagonist at 5-HT2A serotonin receptors. It also exhibits moderate affinity for histamine H1 receptors and alpha1-adrenergic receptors. The My Cite kit includes a sensor that detects tablet ingestion and transmits data to a wearable patch.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARAMINE and ABILIFY MYCITE KIT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARAMINE is: Intravenous infusion: 1-10 mg initially, then 0.5-5 mg/hr titrated to blood pressure. Intramuscular or subcutaneous: 2-10 mg every 2 hours as needed.. The standard adult dose of ABILIFY MYCITE KIT is: Oral: 10-15 mg once daily; dose range 5-30 mg/day; titrate based on response and tolerability. The MYCITE sensor is applied to the tablet; the patch and app are for adherence monitoring only.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARAMINE and ABILIFY MYCITE KIT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARAMINE is classified as Category C. FDA Pregnancy Category C. First trimester: Animal studies show fetal abnormalities; no adequate human studies. Second/third trimester: Risk of maternal hypertension, reduced uterin. ABILIFY MYCITE KIT is classified as Category C. First trimester: Limited human data; animal studies show developmental toxicity (reduced fetal weight, delayed ossification) at doses similar to human exposure. Second/third trimes. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.